objective: most   neonates admitted to neonatal wards do not tolerate sufficient milk.  recently the effect of erythromycin on increasing feeding tolerance in neonates has been studied. in this study the effectiveness of oral, high dose erythromycin a prokinetic agent was used to enhance feeding tolerance in these neonates.  methods: this prospective randomized controlled clinical trial was con...

This study was conducted to investigate the effects of using whole wheat in choice feeding on performance, egg quality, and income laying hens. In study, a total 160-Hyline W-80 white commercial hens aged 28 weeks were divided into four treatment groups fed for 84 days. The as follows: 1) Control (C, standard hen feed), 2) C feed+choice continuously with separate cup (CW), 3) feed+weekly interm...

Aspiration pneumonia is common in older people. To reduce the risk of aspiration pneumonia, maintenance of good oral hygiene is important and medications affecting salivary flow or causing sedation are best avoided, if possible. The use of H2 blockers and proton-pump inhibitors should be minimised. Different compensatory and facilitation techniques can be applied during oral feeding. Hand feedi...

Formaldehyde (FA) is a very toxic pollutant. FA in indoor air has a negative effect on human health and should be removed by ventilation or by conversion to non-toxic products. The formaldehyde dehydrogenase (FdDH), a NADand glutathione-dependent enzyme from recombinant methylotrophic yeast Hansenula polymorpha, was tested for its ability to oxidize airborne FA. A continuous fluidized bed biore...

Nonpoint source nitrogen is recognized as a significant water pollutant worldwide. One of the major contributors is agricultural drainage line water. A potential method of reducing this nitrogen discharge to water bodies is the use of immobilized denitrifying sludge (IDS). Our objectives were to (1) produce an effective IDS, (2) determine the IDS reaction kinetics in laboratory column bioreacto...

Background During the chronic myelogenous leukemia (CML) the Bcr-Abl oncoprotein is produced, which leads to unregulated cell proliferation. CML is treated with one of several targeting therapies such as imatinib, (formerly STI-571 [Glivec; Novartis, Switzerland]) a selective inhibitor that blocks tyrosin kinase activity of the Bcr-Abl oncoprotein. Apart from the second generation Bcr-Abl inhib...